Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources
January 11, 2024
-
BUSINESS New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
-
REGULATORY Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister
January 10, 2024
-
ORGANIZATION FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
-
BUSINESS Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
-
BUSINESS Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
-
BUSINESS After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
-
REGULATORY FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
-
TRENDS Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
-
BUSINESS Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
-
REGULATORY Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
-
REGULATORY (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
-
BUSINESS Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
-
ORGANIZATION Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
-
REGULATORY Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
-
REGULATORY Japan to Cut Drug Prices by 0.97% on Healthcare Cost Basis in FY2024
December 20, 2023
-
REGULATORY Gist of FY2024 Drug Pricing Reform
December 20, 2023
-
COMMENTARY Women’s Health Drugs on a Roll, Further Growth Expected as Public Awareness Rises
December 19, 2023
-
REGULATORY Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
-
BUSINESS Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
December 15, 2023
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…